Page last updated: 2024-12-09

(4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**(4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylate** is a chemical compound with a complex structure. Let's break down its components and potential significance:

**Structure:**

* **4-Ethyl-2-oxochromen-7-yl:** This part indicates a **chromone** derivative. Chromones are heterocyclic compounds containing a pyrone ring fused to a benzene ring. The 4-Ethyl indicates an ethyl group attached at the 4th position of the chromone ring, and 2-oxo signifies a carbonyl group (C=O) at the 2nd position.
* **Furan-2-carboxylate:** This part refers to a **furan** derivative. Furans are five-membered heterocyclic rings containing one oxygen atom. The 2-carboxylate signifies a carboxyl group (-COOH) attached at the 2nd position of the furan ring.

**Importance for Research:**

The specific importance of (4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylate depends on the research area. However, given its structure, this compound might be of interest for:

* **Medicinal Chemistry:** Chromones and furans are known for their diverse biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. This compound could be explored for its potential therapeutic applications.
* **Organic Chemistry:** The compound might be used as a building block or intermediate in synthetic chemistry to create new and complex molecules with desired properties.
* **Materials Science:** Chromones and furans can exhibit interesting optical and electronic properties, potentially making this compound useful for developing new materials.

**Note:** The compound's specific properties and importance are likely tied to a specific research project or application. Without further context, it is impossible to definitively state why it is significant. To understand its importance, you would need to know the specific research question or application in which it is involved.

Cross-References

ID SourceID
PubMed CID807412
CHEMBL ID1498450
CHEBI ID149820

Synonyms (20)

Synonym
OPREA1_867697
OPREA1_497821
MLS001083053 ,
smr000664873
(4-ethyl-2-oxochromen-7-yl) furan-2-carboxylate
CHEBI:149820
HMS2965L12
AKOS016357741
CHEMBL1498450
STL458531
4-ethyl-2-oxo-2h-chromen-7-yl furan-2-carboxylate
cid_807412
2-furancarboxylic acid (4-ethyl-2-oxo-1-benzopyran-7-yl) ester
furan-2-carboxylic acid (4-ethyl-2-keto-chromen-7-yl) ester
(4-ethyl-2-oxidanylidene-chromen-7-yl) furan-2-carboxylate
bdbm47916
432006-53-6
sr-01000242089
SR-01000242089-1
eim07-13523
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acid sphingomyelinaseHomo sapiens (human)Potency12.589314.125424.061339.8107AID504937
glucocerebrosidaseHomo sapiens (human)Potency7.07950.01268.156944.6684AID2101
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency17.42085.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency17.42085.804836.130665.1308AID540253; AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency25.92905.804816.996225.9290AID540253
gemininHomo sapiens (human)Potency5.80480.004611.374133.4983AID624296
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3C-like protease, partialInfectious bronchitis virusIC50 (µMol)2.96201.08505.60679.8110AID1890
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]